World Drug Delivery Summit
Florida A&M University, USA
Title: Nanoparticle constructs to overcome the barriers in lung cancer
Biography: Mandip Singh
Lung cancer is the leading cause of deaths in the United States than any other disease. Non-small cell lung cancer (NSCLC) accounts for 85 percent of all lung cancers. Poor survival rates in NSCLC patients are due to limited efficiency of systemic or oral chemotherapy. Vascular endothelial growth factor (VEGF) over-expression is associated with poor survival. Recently, new approaches in the treatment of lung cancer with novel drugs that selectively inhibit tumor blood supply thus controlling cancer cell survival, proliferation and/or metastasis in combination with conventional anticancer or antiangiogenic drugs have generated clinical interest. DIM-C-pPhC6H5 (DIM-P), a c-substituted diindolylmethanes is novel anti-cancer agent. One of the objectives in my laboratory is to formulate tumor homing pegylated CREKA peptide coated nanolipid carriers of DIM-P and investigate its antitumor activity and antiangiogenic potential for treatment of lung cancer. Further, another objective in my laboratory is to overcome the stromal barriers for tumor penetration by using antifibrotic agents like Telmisartan in combination with nanoparticles. Our results have shown that agents like Telmisartan and Losartan play a significant role in enhancing tumor penetration by reducing collagen levels in tumors and also by inducing apoptosis.